hrp0082lbp-d3-1005 | (1) | ESPE2014

A 2-Year Multi-Centre, Open Label, Randomized Two Arm Study of Genotropin Treatment in Very Young Children Born Small for Gestational Age: Early Growth and Neurodevelopment

De Schepper Jean , Vanderfaeillie Johan , Mullis Primus-E , Rooman Raoul , Matthews Lisa , Dilleen Maria , Browning Richard , Gomez Roy , Wollmann Hartmut

Background: There are limited data available on the efficacy and safety of GH treatment in very young (<30 months) short children, born small for gestational age (SGA).Objectives: To determine the effect of 24 months of GH treatment on body height, BMI, and head growth as well as overall psychomotor development (using the Bayley Scale of Infant Development (BSID-II)) and demonstrate its safety in young (aged between 19 and 29 months) short SGA childr...

hrp0084p1-19 | Bone | ESPE2015

Bone–Muscle Unit Assessment with pQCT in Children with Inflammatory Bowel Disease Following Treatment with Infliximab

Altowati Mabrouka , Malik Umm-Ie-Salma , Shepherd Sheila , Mcgrogan Paraic , Russell Richard , Ahmed Faisal , Wong S C

Background: Biologic therapy may improve bone health, body composition, and muscle function in children with inflammatory bowel disease but the extent of improvement are unclear.Objective and hypotheses: To evaluate bone and muscle mass in children with inflammatory bowel disease (IBD) following infliximab (IFX) therapy.Method: Prospective longitudinal study of 19 children (12M), 17 Crohn’s disease (CD), one ulcerative colitis...

hrp0084p2-359 | Fat | ESPE2015

FTO rs9939609 Polymorphism is Associated with the Presence of Obstructive Sleep Apnoea in Obese Youth

Kao Kung-Ting , Alexander Erin , Harcourt Brooke E , Saffery Richard , Wake Melissa , McCallum Zoe , Werther George , Sabin Matthew

Background: Emerging evidence suggests FTO polymorphisms are associated with obesity-related comorbidities including type 2 diabetes (T2DM), hypertension and polycystic ovarian syndrome (PCOS). However association of FTO with other comorbidities such as obstructive sleep apnoea (OSA) in paediatric populations is less clear.Objective and hypotheses: To investigate the prevalence of obesity-related comorbidities according to FTO genotype in an obese paedia...

hrp0084p2-534 | Puberty | ESPE2015

Evaluation of Body Proportions in Children with Precocious or Delayed Puberty

Wagner Anaelle , Phan-Hug Franziska , Stoppa-Vaucher Sophie , Elowe-Gruau Eglantine , Dwyer Andrew , Pichard Silvia , Pitteloud Nelly , Hauschild Michael

Background: Over the past 20 years there is growing evidence that onset of puberty and changes in body proportions occur at an earlier age, especially in girls. Several studies have suggested this trend is linked to increasing rates of overweight and obese children. However, data on delayed pubertal trends are scant.Objective and hypotheses: To characterize body proportions of children evaluated for pubertal disorders.Method: Retro...

hrp0086rfc14.2 | Growth : Mechanisms | ESPE2016

Contribution of GHR and IGFALS Mutations to Growth Hormone Resistance – Identification of New Variants and Impact on the Inheritance Pattern

Legendre Marie , Dastot Florence , Collot Nathalie , Duquesnoy Philippe , Cohen Enzo , Sobrier Marie-Laure , Adiceam Paola , Anderson Donald , Baron Sabine , Cabrol Sylvie , Callewaert Bert , Cartigny Maryse , Craen Margarita , Crock Patricia , Ladjouze Asmahane , Lazea Cecilia , Polak Michel , Savendahl Lars , Touzani Asmae , Amselem Serge

Background: Bi-allelic GHR mutations are classically responsible for Laron syndrome, a severe growth hormone (GH) resistance syndrome. A few GHR missense mutations have also been implicated in mild GH resistance or idiopathic short stature. IGFALS mutations are responsible for recessive or semi-dominant short stature with normal GH provocative test contrasting with extremely low IGF-I levels.Objective and hypotheses: To assess the contribution of GHR and...

hrp0095p2-7 | Adrenals and HPA Axis | ESPE2022

Suboptimal cortisol response on ITT and subsequent adrenal insufficiency

Boyle Roisin , Sanderson Jennifer , Purton Daniel , Angela Lucas-Herald , McNeilly Jane , Mason Avril , Wong Jarod , Guftar M Shaikh , Ahmed Faisal

Background: Insulin Tolerance tests (ITT) have long been considered the gold standard for dynamic function testing of the hypothalamo-pituitary-adrenal (HPA) axis. Sub-optimal cortisol responses during an ITT in children may be found in children during ITT without a previous clinical suspicion of Adrenal insufficiency (AI). It is not clear what the clinical significance of this is and whether all of these children require formal synacthen testing.<p class=...

hrp0089rfc6.2 | Fat, Metabolism and Obesity | ESPE2018

IGF-I at Four Months Associates to Visceral and Subcutaneous Adipose Tissue at 7 Years of Age

Kjellberg Emma , Roswall Josefine , Andersson Jonathan , Bergman Stefan , Kullberg Joel , Dahlgren Jovanna

Objectives and Study: Insulin-like growth factor I (IGF-I) regulates fetal and infant growth and is influenced by nutrition during infancy. Breast fed children have lower IGF-I levels than formula fed infants and the reason is partly explained by lower levels of protein and higher level of polyunsaturated fatty acids (PUFA) in breast milk compared to formula. Environmental factors, such as nutrition, have long-lasting influences on hormone secretion and on future metabolic hea...

hrp0086p1-p630 | Growth P1 | ESPE2016

GH-Pattern with High Trophs are Often Found after Daily sc rhGH-Injection in Children

Lundberg Elena , Andersson Bjorn , Kristrom Berit , Rosberg Sten , Albertsson-Wikland Kerstin

Background: Endogenous GH pattern is characterized by high peaks (growth signal) and low trophs (metabolic signal). Exogenous GH is given by subcutaneous injection (scGH-injection) daily at bedtime.Objective and hypotheses: To study the factors influencing intra-/interindividual variation of pharmacokinetics and pattern of scGH-injection in GH treated children.Method: One hundred and twenty eight subjects followed yearly ≤ 8 ...

hrp0086p1-p631 | Growth P1 | ESPE2016

Are the GH Treatment Doses in Use within Secretion Rates of Healthy Children?

Lundberg Elena , Andersson Bjorn , Kristrom Berit , Rosberg Sten , Albertsson-Wikland Kerstin

Background: GH-secretion rates for children ranges in pre/early puberty 0.1–11 U/24 h and during mid-puberty 4–40 U/24 h. This can be used to optimize the rhGH treatment doses in children.Objective and hypotheses: To calculated the bioavailable rhGH in relation to injected dose and compare this to GH-secretory rate in healthy children; and to investigate factors influencing bioavailability.Method: One hundred and twenty e...

hrp0084p2-219 | Bone | ESPE2015

Early Increase of the Bone Formation Marker PINP is in a Higher Degree Related to Growth Response Compared to Bone Mineralization in GH Treated Prepubertal Children

Decker Ralph , Andersson Bjorn , Swolin-Eide Diana , Magnusson Per , Kristrom Berit , Albertsson-Wikland Kerstin

Background: It has been reported that short-term increases of the bone formation markers intact amino-terminal propeptide of type I procollagen (PINP), bone-specific alkaline phosphatase (BALP) and osteocalcin display different temporal patterns. In adults, the biphasic model of GH action in bone remodelling shows that GH treatment results initially in an increased bone resorption with a concomitant bone loss, which later on is followed by increased bone formation. In children...